US 12,385,905 B2
Method for the formation and use of an immunolabeling complex
Per Fogelstrand, Mölndal (SE); and Ulf Yrlid, Gothenburg (SE)
Assigned to Kromnigon AB
Filed by Kromnigon AB, Gothenburg (SE)
Filed on Feb. 8, 2022, as Appl. No. 17/667,153.
Application 17/667,153 is a continuation of application No. 15/538,691, abandoned, previously published as PCT/SE2016/050031, filed on Jan. 19, 2016.
Claims priority of application No. 15500481 (SE), filed on Jan. 21, 2015; and application No. 15506405 (SE), filed on May 20, 2015.
Prior Publication US 2022/0155288 A1, May 19, 2022
Int. Cl. G01N 33/542 (2006.01); G01N 33/53 (2006.01); G01N 33/58 (2006.01)
CPC G01N 33/542 (2013.01) [G01N 33/5306 (2013.01); G01N 33/58 (2013.01); G01N 33/583 (2013.01)] 7 Claims
OG exemplary drawing
 
1. A method for forming an immunolabeling complex for use in contacting with a sample, wherein the method comprises:
providing a biotinylated primary antibody comprising a primary antibody conjugated with a plurality of biotin molecules;
providing a monovalent biotin-binding composition labeled with a reporter element, the monovalent biotin-binding composition comprising at least one of monovalent streptavidin or traptavidin, wherein the monovalent biotin-binding composition is conjugated with the reporter element, and wherein the reporter element comprises a fluorochrome;
mixing, in a liquid phase in a reaction vessel, the biotinylated primary antibody with the labeled monovalent biotin-binding composition under conditions that form the immunolabeling complex; and
adding a blocking agent to block unbound portions of the monovalent biotin-binding composition after the biotinylated primary antibody has formed a complex with the labeled monovalent biotin-binding composition to thereby form the immunolabeling complex, wherein the blocking agent comprises free biotin, and wherein the immunolabeling complex is a unit formed in absence of the sample.